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 Abstract: 
Background: A higher cardiovascular morbidity and mortality has been observed in patients with 
bipolar disorder (BPD) or schizophrenia, partly due to an increased risk of hypertension (HTN), 
or a less effective care of it. This systematic review and meta-analysis, presents a critical 
appraisal and summary of the studies addressing the risk of HTN, or the differences in its care, 
for those with schizophrenia or BPD.     
Methods: Prospective studies were searched in PubMed, Embase, PsycINFO, Scopus, and the 
Web of Science, from database inception to June 2017. A meta-analysis was undertaken to 
obtain pooled estimates of the risk of HTN.  
Results: Five studies reporting the risk of HTN, and five studies presenting differences in its 
clinical care, were identified. An increased risk of HTN was observed for BPD patients, with an 
overall Incidence Rate Ratio 1.27(1.15-1.40). The pooled Incidence Rate Ratio of HTN for those 
with schizophrenia was 0.94 (0.75 – 1.14). A poorer care of HTN (lower rates of screening, 
prescription, and adherence) was reported in four studies of schizophrenia, and two of BPD 
patients, compared to people without these conditions.    
Limitations: reduced number of studies on risk and care of HTN on patients with BPD or 
schizophrenia. 
Conclusions: Limited evidence suggests that patients with BPD have a higher risk of HTN. 
Patients with schizophrenia and BPD receive poor care of HTN. Understanding the risk of HTN, 
and the differences in its care, is essential for clinicians to reduce the cardiovascular morbidity 
and overall mortality of these patients. 
Key words: Hypertension, Bipolar disorder, schizophrenia, healthcare disparities, systematic 
review 
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Introduction 
It is estimated that, 184 million disability adjusted life years (DALY), 7% of the total DALYs 
lost globally, are attributable to mental disorders. This represents nine million years of life lost 
(YLLs), and 175 million years lived with disability (YLDs) worldwide.(Walker et al., 2015; 
Whiteford et al., 2013) The life expectancy in patients with mental disorders is reduced between 
one and 32 years, with cardiovascular (CV) disease being the biggest contributor to these 
premature deaths.(Colton and Manderscheid, 2006; Viron and Stern, 2010; Walker et al., 2015) 
Patients with severe mental illnesses, including schizophrenia and bipolar disorder (BPD), have 
the highest mortality rate, among all patients with mental disorders.(Walker et al., 2015) Four 
recent metanalyses have reported an increased risk of acute CV events for patients with 
schizophrenia and BPD.(Fan et al., 2013; Li et al., 2014; Prieto et al., 2014; Correll et al., 2017) 
One explanation for the increased risk of CV events in patients with severe mental disorders 
could be the higher incidence of CV risk factors, such as hypertension (HTN), in this group. 
HTN has 40% prevalence in adults worldwide and it accounts for an estimated 13% of total 
annual deaths and 4% of total DALYs.(WHO, 2010; Forouzanfar et al., 2015) Another possible 
explanation for the increased CV risk among patients with mental illness is that they have poorer 
access to preventive interventions including blood pressure control.(Viron and Stern, 2010; 
Mitchell and Lawrence, 2011; Mitchell et al., 2009)  
Evidence in this area is still insufficient to inform effective management of HTN in patients with 
schizophrenia or BPD. On one hand, the studies included in previous reviews of CV risk factors 
among people with mental illness did not investigate patients with schizophrenia or BPD 
specifically, they reported risk of HTN only when it was associated with other outcomes, or they 
had a cross sectional design.(Meng et al., 2012; Pan et al., 2015; Vancampfort et al., 2015b; 
Vancampfort et al., 2013) On the other hand, the studies included in previous reviews on the 
potential inequalities in the management of HTN in people with mental illness did not assess 
specifically patients with schizophrenia or BPD, have included only subtypes of them, many 
studies did not have a comparison arm, and no studies published after 2011 have been 
reviewed.(De Hert et al., 2011; Morrato et al., 2008; Kilbourne et al., 2008; Weiss et al., 2006; 
Nasrallah et al., 2006; Falissard et al., 2011) However, to our knowledge no systematic review 
has critically appraised and summarized the prospective studies reporting the risk of HTN in 
patients with schizophrenia or BPD, or comparing the management of HTN for those with and 
without these disorders. In order to stablish good control of CV risk, it is essential for clinicians 
to know if patients with a specific diagnosis of schizophrenia or BPD have a higher risk, and 
poorer care, for HTN, which has its own clinical management.(National Institute of Health and 
Care Excellence 2016) Strong evidence in this area could inform a better control of HTN, which 
should lead to a lower CV morbidity and mortality.   
This paper will test the hypothesis that patients with schizophrenia or BPD, observed in available 
studies, have a higher risk of developing HTN, and receive poorer care for it, than those without 
each of these disorders. This systematic review and meta-analysis, presents a critical appraisal 
and summary of the studies that examined the risk, and differences in the clinical care, for HTN 
in patients with schizophrenia or BPD.   
 
Methods 
The Meta-analysis Of Observational Studies in Epidemiology (MOOSE) criteria were used to 
undertake this review and meta-analysis (Supplement 1).(Stroup et al., 2000) 
We aimed to identify studies in compliance with the following inclusion criteria: 
1) Cohort study design  
2) Reporting of original research data 
3) Schizophrenia or BPD as exposure 
4) Reporting as outcome either risk of HTN, or differences in its clinical care (including 
screening, diagnosis, treatment, or adherence to medication), for patients with and without 
schizophrenia or BPD. 
Studies were excluded if they were:  
1) Conducted in specific patient sub-populations (e.g. patients receiving specific medication)  
2) Reporting a composite outcome (e.g. metabolic syndrome) unless separate results for HTN 
had been provided. 
3) Not prospective. 
The following search strategy was used:  ((("Schizophrenia"[Mesh]) OR "Bipolar 
Disorder"[Mesh])) AND (((("Hypertension"[Mesh]) OR hypertens*) OR blood pressure) OR 
high blood pressure). Studies were identified from PubMed, EMBASE, PsycINFO, Scopus, and 
the Web of Science, from inception of the database until the 28
th
 June 2017.  The titles and 
abstracts of all the references identified in the initial search were checked against the inclusion 
criteria.  The studies cited by the papers fitting the inclusion criteria, and relevant reviews, were 
checked for inclusion. Similarly, the papers that have cited the studies fitting the inclusion 
criteria were also searched in the Web of Science and considered for inclusion. There were no 
restrictions on the basis of language, sample size or duration of follow-up. Authors of the studies 
were contacted in some cases, as similarities between articles indicated the possibility of multiple 
publications from the same cohort. Where studies reported results from the same population, data 
were taken from the longest follow-up. Two doctors (LA and IF) conducted all the searches, 
extracted the data using a predefined template, and assessed the quality of the studies fitting the 
inclusion criteria. The Quality Assessment Tool for Observational Cohort and Cross-Sectional 
Studies of the National Institute of Health (USA) was used to assess the risk of bias, and overall 
methodological quality, of the studies.(National Institute of Health 2016)  
Meta-analyses were undertaken to obtain pooled estimates of the risk of HTN among patients 
with BPD and also among those with schizophrenia. A random effects model was used to 
estimate pooled effect size.(Der Simonian and Kacker, 2007)  The heterogeneity between studies 
was measured using I-squared index,  that represents the percentage of the total variation which 
is due to heterogeneity rather than chance, and is preferred to other methods because it does not 
inherently depend on the number of studies in the meta-analysis. Given the small number of 
studies in our analysis I-Squared was chosen to avoid other estimates that perform poorly under 
such circumstances.(Higgins et al., 2003)  Chi-squared statistic was used to test the significance 
of the heterogeneity. When a study reported results as adjusted odds ratios (OR), the ORs were 
used as proxy of Cox hazard ratios, since the proportions of people with hypertension was 
relatively small, and the time unit used was narrow.(Steele, 2005) Studies that reported incidence 
rate ratio (IRR) based on a Poisson regression model, using person-time as denominator, or 
hazard ratios based on Cox regression model, were combined as these estimates, have fairly 
similar interpretation.(Sedgwick, 2012a; Sedgwick, 2012b) If a study that reported estimates for 
each age category, and for the whole sample, we included in the metanalysis the estimates 
obtained from the full data, in compliance with other estimates included. When a study reported 
estimates for each gender category separately, and not estimates based on the whole sample were 
reported, estimates for each gender were included in the metanalaysis independently. If a study 
presented results from a multivariable model exploring the association between schizophrenia or 
BPD and HTN, and then further models were built to explore potential explanatory factors of the 
association, only the results from the first multivariable model were included in the metanalysis. 
No attempt was made to test possible publication bias, small study effect or other irregularities, 
using funnel plots or other methods, due to the small number of studies included, that renders 
most methods inappropriate.(Borenstein et al., 2009)  All statistical analyses were conducted 
using the software STATA version 14. 
The studies that reported differences in management of HTN among patients with schizophrenia 
and BPD were very heterogeneous in design and no meta-analysis could be conducted either.  
Therefore, a narrative summary of these results is also presented. 
 
Results 
The electronic search produced 19787 references. A total of ten studies published between 2006 
and 2016, reporting on the risk of HTN, or differences in its management, among patients with 
schizophrenia or BPD met the inclusion criteria and were included in the review. Details of 
references identified in every stage of the search are presented in figure one. All the studies had a 
large sample size, reliable measures of exposures and outcomes, long follow up, robust analyses 
and rigorous methods to minimize sampling error, bias, and confounding. The score in the 
quality assessment tool was ≥10/14 in all of them, and they were all considered to be of good 
methodological quality, and relevant for the question being raised in this review (National 
Institute of Health 2016) (Supplement 2).   
Five studies estimated the associations between BPD or schizophrenia and risk of HTN. Four 
studies compared the risk of HTN in patients with and without BPD(Stein et al., 2014; Perez-
Pinar et al., 2016; Johannessen et al., 2006; Chien et al., 2013) and two of them additionally 
compared the risk of HTN for those with and without schizophrenia.(Perez-Pinar et al., 2016; 
Johannessen et al., 2006) Finally, one study compared risk of HTN for patients with and without 
schizophrenia only.(Crump et al., 2013) Table one shows the characteristics of these studies. 
They had been conducted in America, Asia and Europe. All studies were population based, their 
sample size ranged from 98714 to 6097834 and follow up lasted between five and 25 years. Only 
two of the studies that estimated risk of HTN for patients with BPD reported a significant 
association.(Johannessen et al., 2006; Chien et al., 2013) In four studies, routinely recorded 
clinical diagnoses of BPD or Schizophrenia and HTN, collected in a single country, were used 
(Johannessen et al., 2006; Chien et al., 2013; Perez-Pinar et al., 2016; Crump et al., 2013) 
However, in one study the WHO Composite International Diagnostic Interview was used to 
assess BPD in participants from 19 countries, who were also asked if, and when, had they been 
diagnosed of HTN.(Stein et al., 2014) This study had a large sample size but it was smaller than 
in others, which resulted in an estimate with a larger confidence interval. Given the 
methodological differences between the study by Stein et al(Stein et al., 2014) and the other 
three studies on BPD patients, it was decided not to include this study in the primary pooled 
estimate for risk of HTN, and include it in a sensitivity analysis.  
The pooled Incidence Rate Ratio (IRR) of HTN for patients with BPD across the studies 
considered primarily, was 1.27 (95% CI: 1.15-1.40) (Figure 2). The heterogeneity between 
studies was not significant, I-squared = 32.6%, p=0.227. The inclusion of the study by Stein et 
al, attenuated the pooled estimate slightly and introduced substantial heterogeneity. However, the 
association remained significant, IRR of HTN for patients with BPD was, 1.19 (95% CI: 1.01-
1.37) I-squared = 71.4%, p=0.015 (Supplement three).(Stein et al., 2014) 
Only one of the three studies that estimated the risk of HTN for patients with schizophrenia 
reported a significant association; HR: 1.17 (1.05-1.29) p=0.003.(Perez-Pinar et al., 2016) 
Another one reported that the risk of HTN was significantly lower for women with 
Schizophrenia, but not significantly different for men.(Crump et al, 2013) The last one reported 
no significant association between schizophrenia and HTN.(Johannessen et al., 2006) The pooled 
IRR, was 0.94 (0.75 – 1.14), not significant, while the heterogeneity was substantial, 90.7%, p 
<0.001 (Supplement four). This heterogeneity could be explained by the different country and 
age of participants and the different results reported across studies. The exclusion of any of the 
studies, did not reduce the heterogeneity by more than 5%. 
Five studies compared the management of HTN for patients with and without schizophrenia, and 
two studies for those with and without BPD. The characteristics of these studies are presented in 
table two. They had been conducted in America, Asia, and Europe. The sample size ranged from 
485 to 2454844 and the follow up was between 1 and 35 years. All studies used clinical records 
but in two of them datasets were completed with epidemiological surveys.(Lahti et al., 2012; 
Laursen et al., 2014) One study only included patients with HTN at baseline.(Kim et al., 2010) 
One study reported that schizophrenia patients were approximately half as likely to have their 
blood pressure recorded.(Roberts et al., 2007) Another one found that patients with 
schizophrenia or BPD had lower prescription rate of angiotensin-converting-enzyme inhibitors, 
or angiotensin receptor blockers, but higher use of diuretics.(Laursen et al., 2014) Another study 
found that patients with schizophrenia had lower rate of prescription of antihypertensive 
medication.(Lahti et al., 2012) With regards to adherence to HTN medication, one study reported 
it to be lower for patients with schizophrenia or BPD (Kim et al., 2010) and another one found 
no association between schizophrenia and adherence.(Owen-Smith et al., 2016) 
Discussion 
A limited number of studies of good quality have investigated the risk of developing HTN for 
patients diagnosed with BPD or schizophrenia. The results of the meta-analyses suggest that the 
risk of HTN is increased by 27% (15% to 40%) for those with BPD, while it does not appear to 
be an increased for those with schizophrenia. The differences in the clinical care of HTN for 
patients with and without BPD or schizophrenia, have been studied in a small number of papers 
that observed very different outcomes. However, the evidence presented in these studies suggests 
that patients with schizophrenia or BPD have poorer care of HTN than people without these 
conditions.  
To our knowledge this is the first systematic review that observes the risk of developing HTN 
among BPD and schizophrenia patients. The comprehensive search and critical assessment of 
studies conducted for this review allows for the estimation of the associations between BPD, 
schizophrenia and HTN obtained on a large number of patients. However, the reduced number of 
available studies represents a limitation of this paper. This may be consequence of publication 
bias as studies reporting not significant associations are less likely to be published.(Chapman et 
al., 2009) Some tools to assess the quality of systematic reviews require the presentation of a list 
of excluded studies, which is not presented in this paper.(AMSTAR 2007) The MOOSE criteria 
were used to undertake this review and meta-analysis, which, for accuracy and conciseness, 
recommends reporting only the number of full texts assessed and excluded. The MOOSE criteria 
is proposed in this type of studies by the Enhancing the QUAlity and Transparency Of health 
Research (EQUATOR) Network, and is widely used by systematic reviewers.(Stroup et al., 
2000) Even though it was not made publically available, a protocol for this review, designed by 
the authors before the study was conducted, was followed.  The different approach of clinicians 
to patients with psychiatric conditions may have resulted in poorer recording of blood pressure in 
patients with schizophrenia and BPD.(Viron and Stern, 2010)  This may have led previous 
studies, (Johannessen et al., 2006) and this review, to underestimate the risk of HTN for patients 
with schizophrenia and BPD.  
The medication that patients with schizophrenia or BPD take may affect the risk of developing 
HTN. The pharmacological effect of different antidepressants and antipsychotics on HTN has 
been observed in other studies.(Correll et al., 2015; Liao et al., 2011) The positive effect of drugs 
in the mental health of these patients may also result in some of them adopting a healthier 
lifestyle, having better access to health services, and subsequently reducing the risk of HTN. 
Another factor that may be involved in the risk of HTN for those with schizophrenia and BPD is 
the high level of sedentary behavior observed in these patients.(Stubbs et al., 2016a; 
Vancampfort et al., 2016) The disruptions of neuroregulatory and neuroendocrine systems may 
also play a role on the association between severe mental illness and HTN.(Nousen et al., 2013; 
Poulter et al., 2015) However, this review did not analyse the role of potential explanatory 
factors, such as medication, for the associations between BPD or schizophrenia and HTN. This 
may be a limitation of this paper and also an area to be addressed by future studies. The 
mechanisms for the association between severe mental illness and HTN are still not well 
understood partly because the pathophysiology of HTN is largely unknown.(Poulter et al., 2015)  
The not significant association between schizophrenia and HTN, that we have observed in this 
review, is consistent with a recent systematic review of cross-sectional studies that reported that 
the pooled prevalence of HTN was increased for those with severe mental illness, but this 
difference was not statistically significant.(Vancampfort et al., 2015b) 
Many factors affect the healthcare of patients with BPD and schizophrenia. These include some 
symptoms of the mental health condition such as memory impairment or reduce motivation, 
issues related to the health service, for example the difficulties to book an appointment with the 
doctor, and also wrong beliefs from the clinicians about these patients, such as the 
underestimation of them as capable partners in their own care.(Viron and Stern, 2010) A good 
coordination between all clinicians from primary and secondary care is essential to avoid gaps in 
care that can result in undetected or poorly controlled HTN.  
Clinicians should be aware that patients with BPD have a higher risk of developing HTN, and 
that the healthcare for it is worse among those with BPD or schizophrenia. A good understanding 
of the risk of HTN among people with schizophrenia or BPD is particularly relevant, since it has 
been observed that these patients have an increased prevalence of other CV risk factors that can 
interact with HTN and result in worse CV health.(de Leon and Diaz, 2005; Stubbs et al., 2015; 
Stubbs et al., 2016b; Vancampfort et al., 2015a; Vancampfort et al., 2015b; Wilens et al., 2016) 
Special clinical attention is required, to achieve a good control of all CV risk factors in this 
vulnerable population which could eventually lead to a life expectancy similar to the one of 
people without psychiatric conditions. 
More prospective studies estimating the association and mechanisms of HTN among patients 
with BPD or schizophrenia are required. Further studies are also needed to understand the main 
points where the health care inequalities happen for those with schizophrenia or BPD. Studies on 
health care inequalities could consider comparing differences in outcomes defined by guidelines 
as the main steps of  HTN care (screening, diagnosis, treatment, follow up and control).(National 
Institute of Health and Cae Execellence 2016) All these studies would provide stronger evidence 
on risk of HTN, and the areas of poor healthcare, and could inform innovative interventions to 
improve the CV care and ultimately reduce the CV morbidity and overall mortality of patients 
with BPD or schizophrenia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Author / Year (Country) N Fo 
llow 
up  
Fe
ma 
le 
% 
Age Expo 
sure  
 
Association  Comments 
Johannessen 2006 
(Denmark)  
139037 25 y NR ≥15 Schiz.  
BPD  
IRR: 0.93   
(0.77-1.14) 
p<0.51 
IRR:1.27    
(1.16-1.39) 
p<0.001 
Nationwide data from 
various  
administrative health 
service registers 
Chien 2013 (Taiwan)  766427 5 y NR ≥18 BPD  
 
RR: 1.40    
(1.20–1.62) 
p<0.001 
Data from the 
National Health 
Research Institute 
Crump 2013 (Sweden) 6097834 7y 51 ≥25 Schiz Women: 0.78 
(0.69–0.89) 
Men: 0.84   
(0.76–0.94) 
Data from all persons  
who had lived in 
Sweden for ≥ 2 years 
at start of follow up 
Stein 2014 (Colombia 
Mexico Peru USA China  
Iraq Israel Japan  Belgium 
France Germany Italy 
Netherlands Poland UK 
Portugal Romania Spain  
N.Zealand)  
98714 NR  NR ≥18 BPD  OR: 0.9 (0.7-1.2) Data from the World 
Mental Health 
Survey 
Pérez-Piñar 2016 (UK)  524952 10 y 47 ≥30 Schiz. 
         
BPD 
HR:1.17     
(1.05-1.29) 
p=0.003 
HR: 1.12    
(0.90-1.39) 
p=0.298 
Data from Primary 
Care Records from 
140 London practices 
Table 1. Characteristics of studies reporting risk of hypertension  
Y: years; NR: Not reported; Sciz: Schizophrenia; BPD: Bipolar disorders; IRR: Incidence rate 
ratio; RR: relative risk; OR: odds ratio, HR: hazard ratio.  
 
 
 
 
 N Fo 
llow 
up 
Fe
ma 
le 
% 
Age Exposure Outco
me  
Association Comments 
Roberts 
2007 (UK)  
485 3y NR 21-64 Schiz.   BP 
recor 
ded  
OR: 0.43 p<0.01 Data from Primary 
Care Records from 
22Birmingham (UK) 
practices. 
Kim 2010 
(South 
Korea)  
 
2454844  1y 58 >20 Schiz.  
        
BPD  
Adhere
nce to 
HTN 
treatme
nt 
(CMA) 
Schiz OR: 0.746  
(0.628–0.886) 
BPD OR: 0.793 
(0.644–0.977) 
Data the National 
Health Insurance, 
which covers the 
whole country. 
Lahti 2012 
(Finland)  
10915 35y 47 ≥35 Schiz. HTN 
treat 
ment 
 
HR: 0.37   
(0.22–0.61) 
p<0.001 
Data from the 
National Social 
Insurance of 
People on Medication 
for Chronic Disease 
Laursen 
2014 
(Denmark)  
 
1061532 11y NR ≥10 Schiz. 
 
 
BPD 
CV 
drugs 
use 
 
Schiz: lower use 
of  ACEI/ARB, 
CCB and   beta 
blockers Higher 
use of diuretics 
BPD: lower use 
of ACEI/ARB. 
Higher use of 
diuretics. 
Data from 
Nationwide data from 
various  
administrative health 
service registers and 
the Helsinki Birth 
Cohort Study 
Owen-
Smith 
2016 
(USA)  
1420 1y 56 18-70 Schiz.  Adhe 
rence 
to 
ACEI/
ARB 
(MPR) 
OR: 0.98   
(0.72-1.33) 
Data from medical 
records of 13 Mental 
Health Research 
Network sites 
Table 2. Characteristics of studies comparing management of HTN in patients with and without 
mental health disorders.  
Y: year; Schiz: Schizophrenia; BPD: Bipolar disorder ; CMA: cumulative medication adherence 
scale; ACEI: Angiotensin converting Enzyme Inhibitors; ARB: Angiotensin receptors blockers; 
CCB: Calcium channel blockers; MPR: Medication Possession Ratio 
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Figure 1. Results of literature search 
References identified in the initial search: 19787 
- PubMed: 1416    
- Embase: 2802 
- PsycInfo: 545 
- Scopus: 13574 
- Web of Science: 1450 
Not relevant: 19716 
Selected for full text assessment: 57 
          Studies fitting inclusion criteria: 10 
References of included studies: 415 
Papers citing included studies: 297 
References of reviews: 1483 
Papers citing reviews: 1301 
Previous reviews 
related to this topic: 14 
Selected for full text assessment: 3 
Selected for full text assessment: 
11 
Total Selected for full 
text assessment: 71 
Not relevant: 61 
- HTN not outcome: 21 
- Not prospective: 17 
- Composite exposure: 8 
- No comparison arm: 6 
- BP as continuous variable: 5 
- Other study from same 
population: 2 
- Study on specific subpopulation: 2 
 
  
 
 
Highlights 
 Bipolar disorders are associated with an increased risk of hypertension.   
 There is no evidence of the association between schizophrenia and hypertension.  
 Patients with bipolar disorder or schizophrenia receive a poor care of hypertension 
 
